SCHEMBL838792

SCHEMBL838792

CCOC(Sc1ncnc2c1cnn2-c1ccccc1OC)C(=O)Nc1nc(C)cs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 8/20 0.62
ALDH1A1 P00352 7/20 0.56
MAPT P10636 6/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
MAPK1 P28482 3/20 0.56
LMNA P02545 2/20 0.49
TSHR P16473 2/20 0.49
HPGD P15428 2/20 0.45
TP53 P04637 2/20 0.45
USP2 O75604 1/20 0.45
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
S1PR2 O95136 1/20 0.42
SLC2A1 P11166 1/20 0.42
SLC2A2 P11168 1/20 0.42
SLC2A3 P11169 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839071 0.83 ALDH1A1 (0.52) GCKALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL839726 0.81 GCK (0.47) GCKALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL837918 0.78 GCK (0.72) GCKALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL838541 0.78 GCK (0.72) GCKALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL837917 0.78 GCK (0.72) GCKALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL849512 0.78 GCK (0.89) GCKALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL838702 0.77 GCK (1.00) GCKALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL839008 0.76 GCK (0.75) GCKALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL838250 0.76 GCK (1.00) GCKALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL837764 0.76 GCK (1.00) GCKALDH1A1MAPTSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US claimed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 GCK 1/4885ALDH1A1 1918/4885MAPT 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.